Pfizer’s Lorbrena Receives First Prescription in China for NSCLC Treatment
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the first prescription of its third-generation...
Cancer
Ascentage Pharma’s Lisaftoclax Shows Promising Results in Phase I Trial for Non-Hodgkin Lymphoma
Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...
Novartis Cuts Back on US Development of BeiGene’s PD-1 Inhibitor Tislelizumab
Novartis AG (NYSE: NVS), BeiGene’s partner, revealed in its Q3 2022 earnings report that it...
Bayer Initiates US Recall of TRK Inhibitor Vitrakvi Due to Mold Contamination
Germany-based Bayer (ETR: BAYN) has announced a voluntary recall of a specific lot of its...
Novartis’ Tislelizumab Faces FDA Hurdle in First-Line NSCLC Monotherapy
Novartis disclosed during its Q2 2022 earnings call that the U.S. FDA deemed clinical data...
Genscript’s CAR-T Therapy JNJ-4528 Demonstrates 100% Effective Rate in Long-Term Myeloma Study
Genscript Biotech Corporation (HKG: 1548), a leading China-based Contract Development and Manufacturing Organization (CDMO), has...
Innovent Biologics and Eli Lilly & Co.’s Tyvyt Achieves Primary Endpoints in Phase II ESCC Clinical Study
Innovent Biologics (HKG: 1801), a prominent biotech firm headquartered in Suzhou, China, and Eli Lilly...
Zai Lab’s Optune Approved by China’s NMPA, Offering New Hope for Glioblastoma Patients
Zai Lab Ltd (NASDAQ: ZLAB), a biopharmaceutical company based in China, has received approval from...